DrugPatentWatch Database Preview
Details for Patent: 9,034,908
Email this page to a colleague
See Plans and PricingWhich drugs does patent 9,034,908 protect, and when does it expire?
Patent 9,034,908 protects BENDEKA and is included in one NDA.
This patent has twenty-eight patent family members in fourteen countries.
Summary for Patent: 9,034,908
| Title: | Formulations of bendamustine |
| Abstract: | Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations. |
| Inventor(s): | Sundaram; Srikanth (Somerset, NJ) |
| Assignee: | EAGLE PHARMACEUTICALS, INC. (Woodcliff Lake, NJ) |
| Application Number: | 13/838,090 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,034,908 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 9,034,908
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | Start Trial | Start Trial | FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,034,908
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2867295 | Start Trial | |||
| Canada | 2867343 | Start Trial | |||
| China | 104271135 | Start Trial | |||
| China | 104302291 | Start Trial | |||
| China | 107157988 | Start Trial | |||
| Denmark | 2827863 | Start Trial | |||
| European Patent Office | 2827862 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
